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Abstract
Background: A previous study explored factors discriminating colonization and true infection among non-transplant,
non-neutropenic patients with repeated Aspergillus spp. isolation from lower respiratory samples. The present study
explored the evolution of patients with Aspergillus colonization in that study to determine the percentage of cases
progressing to aspergillosis and time to development.
Methods: Clinical records were retrospectively reviewed (for each patient from his end date in the past study) and
data from all respiratory processes suffered by patients up to April 2015 were recorded. Comparisons of variables were
performed between colonized patients that developed aspergillosis and those that did not. A Kaplan-Meier curve was
used to describe time to development of aspergillosis in chronic obstructive pulmonary disease (COPD) patients for
II-IV stages of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification.
Results: Sixty seven colonized patients were followed, 12 of them (17.9%) developed aspergillosis. Diagnoses included
six tracheobronchitis (4 invasive, 2 simple tracheobronchitis), four pulmonary disease (2 invasive pulmonary aspergillosis,
2 chronic pulmonary aspergillosis), one allergic bronchopulmonary aspergillosis and one pulmonary aspergilloma. Up to
47 (70.4%) of the study patients presented COPD. Among patients developing aspergillosis COPD was more frequent
(100%) than among those that did not develop aspergillosis (35 out of 55; 63.6%) (p = 0.012), as well as GOLD IV patients
were more frequent among COPD patients developing aspergillosis than among COPD patients that did not (50.0 vs. 26.
1%, p = 0.046). Mean time to development of aspergillosis was 18.4 months (median: 8.5) with a wide range (1–58).
Overtime, the percentage of patients developing aspergillosis was significantly higher among GOLD IV patients than
among GOLD II-III patients (p = 0.032).
Conclusions: The high percentage of cases progressing to aspergillosis among colonized patients, especially among
those with COPD (25.5%), stresses the importance of colonization as risk factor, and creates awareness of the possible
change from colonization to invasive disease in GOLD IV patients.
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Background
The significance of Aspergillus colonization is unclear be-
cause it may represent a temporary passage, a long-term
benign carriage or a sign preceding invasive disease, with
scarce information on the length of the incubation period
[1, 2]. A previous study by our group explored implica-
tions of repeated isolation of Aspergillus spp. from lower
respiratory samples in non-transplant, non-neutropenic
patients in an attempt to identify factors helping in dis-
criminating colonization and true infection [3]. One im-
portant finding was the high number of patients with
probable/proven aspergillosis among patients with chronic
obstructive pulmonary disease (COPD) [3], including
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) II patients [4].
The cohort of patients categorized as colonized in the
previous study offered the opportunity to explore the pos-
sible progression and time to development of aspergillosis
in non-transplant, non-neutropenic patients as previously
explored for post-lung transplant patients [5] and patients
with acute myeloid leukemia [6].
The aim of the present follow-up study was to explore
the evolution of colonized patients from the cohort
identified in the previous study [3] to determine the
percentage of cases progressing to aspergillosis and time
to development.
Methods
A retrospective review of clinical records of patients catego-
rized as Aspergillus-colonized patients in a previous study
[3, 4] was performed. The inclusion criterion was Aspergil-
lus-colonized patients defined as patients with at least two
cultures of lower respiratory samples (good quality sputum)
yielding Aspergillus spp. without dyspnoea exacerbation,
bronchospasm, new pulmonary infiltrates or symptoms at-
tributable to Aspergillus in the previous study. A total of 106
colonized patients were identified in the database of the pre-
vious study, 93 of them surviving at the time of study clos-
ure [3]. Centres (22 centres) that attended these 93 patients
were contacted and invited to participate in the present
follow-up, and 17 of them agreed. In these participating cen-
tres, a total of 67 colonized patients were followed-up.
Clinical records were retrospectively reviewed, and clin-
ical data from all medical visits/hospital admissions due
to respiratory symptoms suffered by these patients
(whether as outpatients or inpatients, and regardless
the aetiology of infections) from the end date of the
past study (individualized for each patient) to April 2015
were recorded. The study protocol was approved by the
Ethics Committee of Hospital Universitario Monteprincipe,
Madrid, Spain.
Demographic data, underlying illnesses, clinical and
radiological data, laboratory data, previous treatments
(corticosteroids, antibiotics, antifungals…), antifungal
treatment and outcome were recorded. The Charlson
comorbidity index and its correction by age [7, 8], the
modified McCabe score (Sabadell score) [9], and the Acute
Physiologic and Chronic Health Evaluation (APACHE)
II score were retrospectively calculated, as well as the
GOLD classification for COPD patients [10]. When
more than one respiratory episode was recorded during
the follow-up period, data from the episode where
aspergillosis was diagnosed or data corresponding to
the last episode (for patients not developing aspergillosis)
were considered.
Diagnoses of tracheobronchitis were always based on
bronchoscopy reports included in clinical records. Simple
tracheobronchitis was considered when the bronchoscopy
report described mucosal inflammation and mucus secre-
tions, and invasive tracheobronchitis when ulceration and
pseudomembrane formation was observed [3, 11]. Diagnosis
of invasive pulmonary aspergillosis was based on a host
factor criterion (COPD), clinical criteria (dyspnoea exacer-
bation, bronchospasm, new pulmonary infiltrates or other
new respiratory symptoms…), and mycological criteria [2].
Chronic pulmonary aspergillosis was considered when
long-term fibrotic lesions with or without necrosis or
cavitations had been recorded in the patient’s clinical
records [3, 12]. Aspergilloma was considered on a radio-
logical basis (upper-lobe, mobile, intracavitary mass)
[12, 13]. Allergic bronchopulmonary aspergillosis (ABPA)
was considered in patients with asthma/cystic fibrosis
based on clinical data (worsening or appearance of new
respiratory symptoms), analytical data (including specific
immunoglobulins) and radiological data [14].
Comparisons of variables between colonized patients
that developed aspergillosis and those that did not were
performed by the χ2 test and the Fisher’s exact test,
when necessary. For quantitative variables, since data
did not show normality in the Kolmogorov – Smirnoff
test, the Kruskal-Wallis and Mann-Whitney tests, when
necessary, were used. For each patient developing asper-
gillosis, time from colonization to infection was calcu-
lated considering the date of his first positive Aspergillus
culture (in the previous study) and the visit/admission
date (in the present follow-up) when the diagnosis of as-
pergillosis was made. A Kaplan-Meier curve was used to
describe time to development of aspergillosis. Statistical
analyses were performed using SPSS v 14 programme
(SPSS Inc., Chicago IL).
Results
Twelve of the 67 colonized patients (17.9%) included in
this follow-up study developed aspergillosis. Table 1
shows characteristics of patients distributed by develop-
ment of aspergillosis or not. During the study period, pa-
tients suffered several episodes of respiratory infections,
the number of episodes being higher among patients
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developing aspergillosis, although the difference did not
reach significance. No differences between groups were
found in values of clinical index/scores or ICU admis-
sion. Forty-seven of the 67 (70.4%) colonized patients
presented COPD: all patients developing aspergillosis
were COPD patients and 35 out of 55 (63.6%) of those
not developing aspergillosis presented COPD, the difference
being statistically significant (p = 0.012). Colonising species
were identified as Aspergillus fumigatus in 46 (68.7%) pa-
tients, Aspergillus niger in three (4.5%) and Aspergillus flavus
in two (3.0%) patients, the remaining being reported as
Aspergillus spp. Non-fumigatus species were isolated from
2/12 (16.7%) patients developing aspergillosis and 19/55
(34.5%) from those that did not (p= 0.313).
CT scan was performed in 29.9% patients: 50% of
patients developing aspergillosis and 25.5% of those that
did not (p = 0.160).
No differences between groups were found in the
number of patients receiving antibiotics or antifungals
prior to the described episode, with quinolones and
voriconazole as most frequent compounds. Antifungal
treatment was more frequently administered during the
described episode in patients developing aspergillosis
(41.7 vs. 3.6%, p = 0.001), being voriconazole the most
frequent compound [4 out of 5 (80%) treated-patients
developing aspergillosis and 1 out 2 (50%) among those
treated-patients that did not]. With respect to previous
intake of steroids, doses >20 mg/day had been taken by
3 out of 12 (25.0%) patients developing aspergillosis and
14 out of 55 (25.5%) patients that did not (p = 1.000),
with 0% and 12.7% (7/55) patients, respectively, having
received cumulative doses >700 mg within the previous
three months (p = 0.355). Although non-significant, the
percentage of patients developing aspergillosis treated
with cumulative doses of 100-700 mg within the previ-
ous three months was higher than among those not
developing aspergillosis (5 out of 12–41.7%- vs. 11 out
of 55–20%-; p = 0.140).
In the subgroup of 47 COPD patients, the percentage
of patients developing aspergillosis was 25.5% (12 out of
47), being the percentage of GOLD IV patients signifi-
cantly higher among patients developing aspergillosis
than among those that did not develop aspergillosis
(50.0% vs. 26.1%, p = 0.046).
Table 2 details data from patients developing aspergillosis.
Most patients were males (75%) and ≥65 years old (83.3%).
Diagnoses included six tracheobronchitis (4 invasive
and 2 simple tracheobronchitis), four pulmonary disease
Table 1 Characteristics of patients distributed by development or not of aspergillosis
Total Developing aspergillosis p
No Yes
n 67 55 12
No. respiratory episodes; median (IQR) 2 (1.0–4.0) 2 (1.0–3.0) 3 (2.0–4.8) 0.061
Age; mean ± SD 73.1 ± 14.9 73.7 ± 15.4 70.2 ± 12.7 0.468
≥70 years 48 (71.6) 49 (72.7) 8 (66.7) 0.729
COPD 47 (70.4) 35 (63.6) 12 (100) 0.012
GOLD category
III 17 (29.3) 14 (30.4) 3 (25.0) 1.000
IV 18 (31.0) 12 (26.1) 6 (50.0) 0.046
Diabetes mellitus II 13 (19.4) 11 (20.0) 2 (16.7) 1.000
Congestive heart failure 9 (13.4) 7 (12.7) 2 (16.7) 0.658
Liver disease 7 (10.4) 5 (9.1) 2 (16.7) 0.600
Chronic renal insufficiency 7 (10.4) 7 (12.7) 0 (0.0) 0.336
Charlson index; mean ± SD 2.4 ± 1.7 2.4 ± 1.8 2.6 ± 1.6 0.744
APACHE; mean ± SD 12.5 ± 5.0 12.1 ± 5.0 14.4 ± 5.0 0.142
McCabe (rapidly fatal) 11 (16.4) 9 (16.3) 2 (16.7) 1.000
ICU admission 5 (7.5) 4 (7.3) 1 (8.3) 1.000
Mechanical ventilation 6 (9.0) 5 (9.1) 1 (8.3) 1.000
Previous steroids intake (3 months) 24 (35.8) 20 (36.4) 4 (33.3) 1.000
Previous antibiotics intake (30 days) 28 (41.8) 22 (40.0) 6 (50.0) 0.538
Previous antifungals intake (30 days) 9 (13.4) 7 (12.7) 2 (16.7) 0.658
Antifungals in the present episode 7 (10.4) 2 (3.6) 5 (41.7) 0.001
For patients without aspergillosis, data correspond to episodes with the highest GOLD/APACHE value. Data are expressed as n (%) except where indicated
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(2 invasive pulmonary aspergillosis and 2 chronic
pulmonary aspergillosis), one ABPA and one pul-
monary aspergilloma. Presence of A. fumigatus in
lower respiratory tract samples were confirmed at the time
of diagnosis (eight patients) or within the previous two
months in 10 out of 12 patients with aspergillosis, lacking
recent positive culture for an 80-years old GOLD IV pa-
tient with invasive tracheobronchitis and the patient with
aspergilloma. CT scans performed in six patients showed
infiltrates (five patients), nodules (three patients), cavita-
tions (one patient) and pleural effusion (one patient),
without halo signs or air crescent signs. No samples for
histopathological confirmation were collected in these
patients. Mean time to development of aspergillosis was
18.4 months (median: 8.5 months), with a wide range (1–58
months). Figure 1 shows overtime the percentage of patients
developing aspergillosis among GOLD II-III patients and
GOLD IV patients. Significant differences were found be-
tween both groups (p = 0.032).
Discussion
Nowadays, approximately 30–50% cases of invasive pul-
monary aspergillosis are diagnosed in non-neutropenic
patients [15], and pre-existing structural disease of the
lungs such as COPD increases the risk for developing in-
vasive pulmonary aspergillosis [16]. A previous study in
our country reported 22.1% of probable invasive pul-
monary aspergillosis among hospitalized COPD patients
with at least one culture positive to Aspergillus [17]. Al-
though several factors (among them, previous colonization,
not sufficiently studied) have been identified, no definitive
data is available to explain why colonization changes to in-
vasive disease [18] with some patients with COPD develop-
ing invasive pulmonary aspergillosis while others do not
[15]. The present study, a follow-up study in patients with
Aspergillus airway colonization, showed that approximately
18% patients developed aspergillosis, this percentage being
higher among patients with COPD (approx. 26%). In the
present series, COPD was the sole risk factor in common
for our non-transplant, non-neutropenic patients develop-
ing aspergillosis, 75% of them presenting GOLD III-IV.
Other conditions compromising immune function and re-
ported to increase the risk of acquiring invasive aspergillosis
as diabetes mellitus or liver cirrhosis [16] were present in
some of the patients developing aspergillosis, but no con-
clusions can be drawn in our study on colonized patients.
Similarly, previous intake of antibiotics and steroids has also
been reported as an increased risk for invasive disease [19],
but in the present series the percentage of patients that had
been treated with antibiotics or high doses of steroids prior
to the index episode was similar in both groups, as there
are common drugs for patients with COPD exacerbations.
Once tissue invasion has occurred, it is well known
that Aspergillus produces a wide range of invasive and
saprophytic syndromes [1], A. fumigatus being the main
responsible species. This range of diseases was also
found in the present study where two patients devel-
oped a saprophytic syndrome (aspergilloma and ABPA)
and, more important from the prognosis perspective,
50% of patients presented an invasive syndrome. The
high mortality rate associated with invasive disease in
non-neutropenic critically ill patients has been attrib-
uted to difficulties in timely diagnosis due to insensitive
and non-specific clinical signs and lack of unequivocal
diagnosis criteria [20]. Diagnosis presents special diffi-
culties in COPD patients since the invasiveness of
procedures to obtain samples for histopathological con-
firmation limits the possibility of fungal evidence be-
cause these procedures are rarely performed in patients
Table 2 Detailed data from patients with aspergillosis
Patient no. Gender Age GOLD Time to aspergillosis
(months)
Diagnosis
1 Male 70–75 IV 6 Aspergilloma
2 Female <50 II 16 ABPA
3 Male 60–69 IV 7 CPA
4 Male >75 II 38 CPA
5 Female >75 III 29 IPA
6 Male 70–75 IV 3 IPA
7 Male >75 IV 58 IT
8 Male >75 II 44 IT
9 Male 60–69 III 10 IT
10 Female >75 IV 6 IT
11 Male >75 IV 3 ST
12 Male 60–69 III 1 ST
ABPA Allergic bronchopulmonary aspergillosis; CPA Chronic pulmonary
aspergillosis; IPA Invasive pulmonary aspergillosis; IT Invasive tracheobronchitis;
ST Simple tracheobronchitis
Fig. 1 Overtime percentage of GOLD II-III and GOLD IV patients
developing aspergillosis among the 47 COPD patients
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suffering from chronic lung disease as late-stage COPD
patients [17, 21]. Therefore, most cases reported in
COPD patients are “probable” [21] as occurred in all
cases in the present series. In this sense, the difficulty
in sample collection in elderly late-stage COPD patients
was probably the reason for the lack of a recent positive
culture in the 80-years old GOLD IV patient with inva-
sive tracheobronchitis in the present study. However,
CT scan and antifungal therapy were markedly more
frequent in patients developing aspergillosis than in
those that did not. CT scan is indicated in cases of sus-
picion of Aspergillus involvement, regardless classical
radiological findings may be less reliable in non-neutropenic
patients [16], as in the present series where none of the pa-
tients presented halo or air crescent signs.
To our knowledge, this is the first follow-up study ex-
ploring the percentage of colonized patients developing
aspergillosis among non-transplant, non-neutropenic pa-
tients. Our results showed a percentage of development
among COPD patients (25.5%) similar to that reported
in pre-transplant colonized cystic fibrosis patients devel-
oping invasive aspergillosis after transplantation (24.6%)
[5]. In cystic fibrosis patients, Aspergillus colonization is
associated with pulmonary exacerbations, and a small
subset of patients develops allergic aspergillosis and very
rarely invasive aspergillosis [5]. However, after trans-
plantation Aspergillus should not be considered so in-
nocuous since the impaired immunity precipitates
invasive syndromes [5].
Our cohort of colonized patients was retrospectively
followed to determine not only the percentage of asper-
gillosis development but also time to development. The
duration of the incubation period of invasive aspergil-
losis remains unknown, probably due to the lack of
knowledge regarding time of exposure, duration of
previous colonization and the relationship between ex-
posure, colonization and invasion [6]. Considering the
lack of specific studies in this field, in the commented
study on colonized cystic fibrosis patients, median time
from transplantation to infection was 42 days [5]. Time
from colonization to infection in our study could be
hardly compared with the reported time from trans-
plantation to infection since post-transplant patients
receive immunosuppressive agents that precipitates an
impaired immunity, making the great difference with
COPD patients. Thus, colonization, percentage of pa-
tients developing aspergillosis and time to aspergillosis
should be necessarily different in COPD patients. In this
sense, the lower percentage of patients developing inva-
sive syndromes (6 out of 47, 12.8%) and the larger time
to develop aspergillosis (8.5 months median time)
among COPD patients in the present study could be re-
lated to the absence of induced impair immunity by im-
munosuppressive agents.
Although this is the largest series of colonized non-
transplant, non-neutropenic patients reporting develop-
ment of aspergillosis, the low number of patients and
the retrospective nature of the study (patients managed
following daily practice without additional investiga-
tional tests) limit the conclusions. The fact that diagnos-
tic criteria were based on those by Bulpa et al. [2] and
not on EORTC/MSG definitions [22] could also be con-
sidered a potential study limitation, but criteria by Bulpa
et al. are commonly used for non-hematological, non-
transplant, non-neutropenic patients [17, 23] since
EORTC/MSG definitions do not include COPD as host
criteria. However, the percentage of patients developing
aspergillosis among colonized COPD patients and the
multicentre nature of the study deserves attention to
study conclusions, regardless the potential variability in
daily practice between centres.
Conclusions
The high percentage of cases progressing to aspergil-
losis among Aspergillus-colonized non-transplant, non-
neutropenic patients, especially among patients with
COPD, stresses the importance of colonization as risk
factor, and creates awareness of the possible change from
colonization to invasive disease in GOLD IV patients.
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